Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1992 1
1996 1
1999 2
2023 0
Text availability
Article attribute
Article type
Publication date

Search Results

5 results
Results by year
Filters applied: . Clear all
Page 1
Fosinopril/hydrochlorothiazide: single dose and steady-state pharmacokinetics and pharmacodynamics.
O'Grady P, Yee KF, Lins R, Mangold B. O'Grady P, et al. Br J Clin Pharmacol. 1999 Sep;48(3):375-81. doi: 10.1046/j.1365-2125.1999.00013.x. Br J Clin Pharmacol. 1999. PMID: 10510149 Free PMC article. Clinical Trial.
AIMS: Fosinoprilat, the active product of fosinopril, is eliminated by an hepatic pathway in addition to the renal pathway shared by other angiotensin converting enzyme inhibitors (ACEIs). ...This is probably due to the dual excretory pathways for fosinoprilat....
AIMS: Fosinoprilat, the active product of fosinopril, is eliminated by an hepatic pathway in addition to the renal pathway shared by …
Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension.
Murdoch D, McTavish D. Murdoch D, et al. Drugs. 1992 Jan;43(1):123-40. doi: 10.2165/00003495-199243010-00009. Drugs. 1992. PMID: 1372856 Review.
Fosinopril is a phosphinic acid prodrug which, after oral administration, undergoes rapid hydrolysis to its active diacid, the angiotensin converting enzyme (ACE) inhibitor fosinoprilat. Unlike other ACE inhibitors, fosinoprilat has a compensatory dual route of elim …
Fosinopril is a phosphinic acid prodrug which, after oral administration, undergoes rapid hydrolysis to its active diacid, the angiotensin c …
Fosinopril: a reappraisal of its pharmacology and therapeutic efficacy in essential hypertension.
Wagstaff AJ, Davis R, McTavish D. Wagstaff AJ, et al. Drugs. 1996 May;51(5):777-91. doi: 10.2165/00003495-199651050-00006. Drugs. 1996. PMID: 8861547 Review.
Comparative trials of monotherapy with fosinopril 10 to 40 mg/day have demonstrated antihypertensive efficacy equivalent to that of sustained release nifedipine 40 mg/day, hydrochlorothiazide 25 to 50 mg/day, enalapril 5 to 10 mg/day amlodipine 5 to 10 mg/day and sustained …
Comparative trials of monotherapy with fosinopril 10 to 40 mg/day have demonstrated antihypertensive efficacy equivalent to that of sustaine …
Fosinopril and hydrochlorothiazide combination versus individual components: lack of a pharmacokinetic interaction.
Uderman HD, Much DR, Brennan J, Delaney CL, Morgenthien EA, Weaver J, Stouffer BC, Chang SY, VanHarken D, Liao W. Uderman HD, et al. Ann Pharmacother. 1999 May;33(5):525-30. doi: 10.1345/aph.18228. Ann Pharmacother. 1999. PMID: 10369612 Clinical Trial.
RESULTS: There was no evidence of any significant effect of HCTZ on the pharmacokinetics of fosinoprilat, based on maximum concentration value, AUC, or cumulative urinary recovery over 24 hours. Fosinoprilat had no clinically important effect on the pharmacokinetics …
RESULTS: There was no evidence of any significant effect of HCTZ on the pharmacokinetics of fosinoprilat, based on maximum concentrat …
Antihypertensive effect of fosinopril, a new angiotensin converting enzyme inhibitor: findings of the Fosinopril Study Group II.
Pool JL. Pool JL. Clin Ther. 1990 Nov-Dec;12(6):520-33. Clin Ther. 1990. PMID: 2149674 Clinical Trial.
For patients with an inadequate blood pressure response after four weeks, doses were doubled during the second four weeks, and hydrochlorothiazide was added during the final four weeks. The patients showed a significant, consistent antihypertensive response in seated and s …
For patients with an inadequate blood pressure response after four weeks, doses were doubled during the second four weeks, and hydrochlor